Dr. Vishisht Mehta, MD

Dr. Mehta practices at Comprehensive Cancer Centers of Nevada in Las Vegas, Nevada.

Dr. Mehta's NPI, 1316346430, was assigned on August 14, 2014. Dr. Mehta holds Nevada license 20682.

Dr. Mehta's primary practice is Comprehensive Cancer Centers of Nevada, at 3150 N Tenaya Way, Las Vegas, NV 89128 in Clark County. The practice phone is (702) 952-3400.

Dr. Mehta's primary practice is Comprehensive Cancer Centers of Nevada in Las Vegas, Nevada. Dr. Mehta is also affiliated with MountainView Hospital. The medical group on file is Comprehensive Cancer Centers of Nevada. Dmand AI also links Dr. Mehta to 3 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mehta practices, 5 sites in all. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Mehta's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Mehta is licensed in Nevada.

CMS data shows 3,629 Medicare services from Dr. Mehta across 22 procedure codes in 2024, for 779 Medicare patients. Medicare paid $218,329 for them.

CMS counts 779 Medicare patients who saw Dr. Mehta in 2024. The largest group is 75 to 84, with 333 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 2.31, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mehta's median patient age at 68, with 51% women.

In 2024, Dr. Mehta wrote 900 Medicare Part D claims for 207 patients. 34% of them were for generic drugs. CMS names the drug for 773 of them, across 18 drugs with 11 or more claims each, at $338,986 in total drug cost. In 2023, CMS named 529 claims across 13 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Mehta for performance year 2024, reported individually. Dr. Mehta accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mehta as offering telehealth.

Dmand AI links 12 papers to Dr. Mehta, published from 2016 to 2023. The most frequent topics are Diagnosis, Differential and Tomography, X-Ray Computed. Dr. Mehta has published most often in Lung India. Dr. Mehta's most frequent co-authors are Priyanka Makkar, MD, Amanda M. Dave, MD and Zachary Scott Depew, MD.

CMS Open Payments shows 83 general payments to Dr. Mehta from 19 drug and device companies from 2020 to 2025. Consulting fees make up the largest share, 39% of the total. Sanofi and Genzyme US Companies paid the most, $11,260.